These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8913545)

  • 1. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T; Yoshinaga K
    Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.
    Nielsen S; Dollerup J; Nielsen B; Jensen HA; Mogensen CE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():19-23. PubMed ID: 9269694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of losartan.
    Goldberg A; Sweet C
    Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
    Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
    Dahlöf B; Keller SE; Makris L; Goldberg AI; Sweet CS; Lim NY
    Am J Hypertens; 1995 Jun; 8(6):578-83. PubMed ID: 7662242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC; Fitzpatrick V; Chrysant S; Francischetti EA; Goldberg AI; Sweet CS
    J Hum Hypertens; 1995 Nov; 9(11):861-7. PubMed ID: 8583463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
    Byyny RL
    Blood Press Suppl; 1996; 2():71-7. PubMed ID: 8913544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan for hypertension.
    Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
    [No Abstract]   [Full Text] [Related]  

  • 12. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
    Weber MA; Neutel JM; Smith DH
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
    Lacourcière Y; Brunner H; Irwin R; Karlberg BE; Ramsay LE; Snavely DB; Dobbins TW; Faison EP; Nelson EB
    J Hypertens; 1994 Dec; 12(12):1387-93. PubMed ID: 7706699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan.
    Hansson L
    Blood Press Suppl; 1997; 1():52-5. PubMed ID: 9285110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
    Goa KL; Wagstaff AJ
    Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension.
    Neki NS; Arora P
    J Indian Med Assoc; 2001 Nov; 99(11):640-1. PubMed ID: 12022207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future role of losartan.
    Hansson L
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
    Tikkanen I; Omvik P; Jensen HA
    J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.